Search clinical trials for: YYC506-T and YYC506-A (phase 1)

Total 1182 results

Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Study to Assess Medication Satisfaction in Patients With Relapsing Remitting Multiple Sclerosis Treated With Copaxone® (CONFIDENCE)

Multiple Sclerosis

United States, Argentina, Austria, Belgium, Croatia, Finland, France, Germany, Ireland, Italy, Mexico, Poland, Puerto Rico, Russian Federation, Spain, Turkey
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)

Optic Neuritis
Sanofi

Completed

FOCUS Fatigue Outcome in Copaxone USers

Multiple Sclerosis

Czech Republic
Shanghai Cell Therapy Research Institute

Unknown

PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST)

Advanced Solid Tumor

China
Taiho Pharmaceutical Co., Ltd.

Completed

Phase III Study of S-1 + Cisplatin vs Cisplatin in Cervical Cancer

Cervical Cancer

Japan, Korea, Republic of, Taiwan
Refnot-Pharm Ltd

Completed

Effect of Refnot on Immunity in Cancer Patients (R-2)

Solid Tumor
Montefiore Medical Center
Rett Syndrome Research Trust

Completed

Pharmacological Treatment of Rett Syndrome With Glatiramer Acetate (Copaxone)

Rett Syndrome

United States
Sheba Medical Center

Unknown

Gait Evaluation in Multiple Sclerosis Patients Treated With Glatiramer Acetate

Multiple Sclerosis

Israel
The First Affiliated Hospital of Soochow University
West China Hospital; Affiliated Hospital of Jiangnan University; The Affiliated... and other collaborators

Recruiting

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid Leukemia

Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia
University of Pennsylvania

Completed

CD4-ZETA Gene Modified T Cells With and Without Exogenous Interleukin-2 (IL-2) In HIV Patients (CD4-ZETA)

HIV-1 Infections

United States
Zeynep Kamil Maternity and Pediatric Research and...

Completed

Postpartum Immediate Contraception in Cesarean Deliveries-Comparison of Two Intrauterine Systems

Intrauterine Systems | Postpartum Immediate Contraception

Turkey
Xiangya Hospital of Central South University
First People's Hospital of Chenzhou; Xiangtan Central Hospital

Recruiting

Efficacy and Safety of Intraventricule Pemetrexed Disodium Administered Via Ommaya Reservoir

Lung Cancer | Leptomeningeal Metastasis

China
Ondokuz Mayıs University

Completed

Changes of GCF Levels of RANKL and Osteoprotegerin in Postmenopausal Osteoporosis

Chronic Periodontitis
Gulhane Training and Research Hospital

Completed

Effect of Different Dietary Therapies on Intestinal Barrier Integrity in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome-IBS

Turkey
John Hale

Recruiting

Antiviral Activity of Oral Probiotics

Lower Respiratory Tract Infection | Upper Respiratory Tract Infection

New Zealand
University of Glasgow

Suspended

B1 and Magnesium Supplements on Glucose Metabolism in Low-carb Dieters (B-Mag)

Diet, Carbohydrate-restricted

United Kingdom
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Universitair Ziekenhuis Brussel

Active, not recruiting

Intratumoral Injection of Autologous CD1c (BDCA-1)+ Myeloid Dendritic Cells Plus Talimogene Laherparepvec (T-VEC) (myDCTV)

Melanoma

Belgium
Teva Branded Pharmaceutical Products R&D, Inc.

Withdrawn

A Multinational, Randomized, Double-blind, Parallel-group, Placebo-controlled Study Assessing the Safety and Tolerability

Relapsing Multiple Sclerosis
Centre Hospitalier Universitaire Vaudois
Ludwig Institute for Cancer Research

Completed

Immunotherapy of Stage III/IV Melanoma Patients

Melanoma

Switzerland
Lawson Health Research Institute
University of Western Ontario, Canada; St. Joseph's Health Care London

Completed

Effects of Probiotics on Rheumatoid Arthritis Patients

Rheumatoid Arthritis

Canada
Pfizer

Completed

Relative Bioavailability Of Palbociclib (PD-0332991) Under Fed And Fasted Conditions

Healthy

United States
Amphia Hospital
Sanofi; TEVA Pharmachemie

Unknown

Optical Coherence Tomography: Glatiramer in Clinically Isolated Syndrome or Early Relapsing Remitting Multiple Sclerosis (MS) (OCTIMS)

Multiple Sclerosis

Netherlands
Kaplan Medical Center

Unknown

Copaxone in Age Related Macular Degeneration

Macular Degeneration

Israel
Johns Hopkins University
University of South Carolina

Completed

Stimulating Language in Subacute StrokE (SLISSE)

Stroke

United States
Castle Creek Pharmaceuticals, LLC

Terminated

Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)

Epidermolysis Bullosa Simplex

United States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
Repertoire Immune Medicines
Merck Sharp & Dohme LLC

Terminated

RPTR-147 in Patients With Selected Solid Tumors and Lymphomas

Lymphoma | Solid Tumor

United States
Rennes University Hospital

Completed

REVADE : Right Ventricular Function and Exercise in Left Ventricular Assist Device Patients : Echocardiographic Study (REVADE)

Left Ventricular Assist Devices Patients

France
Cinnagen

Completed

Safety and Effectiveness of Cinnomer® (Glatiramer Acetate) in Multiple Sclerosis (MS) Treatment in Iran

Relapsing Multiple Sclerosis
Tel-Aviv Sourasky Medical Center
Teva Branded Pharmaceutical Products R&D, Inc.; Medtronic - MITG

Unknown

A Double Blind Placebo Control Study to Assess the Safety,Tolerability and Efficacy of Copaxone in Crohn's Disease (Cop1CD)

Crohns Disease

Israel
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Hepatocellular Carcinoma
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing Mesothelin-CAR-T Cells for Mesothelin Positive Advanced Solid Tumor

Advanced Solid Tumor

China
University Hospital, Lille
Janssen Pharmaceutica N.V., Belgium

Not yet recruiting

Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma (IFM2021-01)

Multiple Myeloma
Bradley A. McGregor, MD
Pfizer

Withdrawn

Avelumab, Palbociclib and Axitinib in Advanced RCC (APART)

Advanced Clear Cell Renal Cell Carcinoma

United States
Ministry of Health, Rwanda

Completed

An Open Label, Blinded Assessor, Trial Comparing Odor Levels Due to Different Hygiene Methods With PrePexTM (RMC-10)

Odor Levels of Study Arms

Rwanda
Taro Pharmaceuticals USA

Terminated

Clinical Equivalence of Two Generic Butenafine Hydrochloride 1% Creams as Compared to Lotrimin Ultra Cream in Patients With Interdigital Tinea Pedis (BNF-0909)

Interdigital Tinea Pedis
Nantes University Hospital

Completed

Treatment of Metastatic Melanoma With Autologous Melan-A/MART-1 Specific CTL Clones

Immunotherapy

France
Masonic Cancer Center, University of Minnesota

Completed

Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer

Metastatic Prostate Cancer

United States
Peking University People's Hospital

Completed

Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China

Upper Respiratory Tract Infection | Skin Infection | Lower Respiratory Infection | Genital Infection | Subcutaneous Tissues Infection

China
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness

Relapsing-Remitting Multiple Sclerosis

United States
Centre Hospitalier Universitaire Vaudois
Immutep S.A.S.

Terminated

Immunotherapy of HLA-A2 Positive Stage II-IV Melanoma Patients (LAG-3/IMP321)

Melanoma

Switzerland
Kanyos Bio, Inc., a wholly-owned subsidiary of...
Pfizer

Recruiting

A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

Celiac Disease

United States, Australia, New Zealand
Hyundai Pharm

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

Contraception

Korea, Republic of
University of Kansas Medical Center

Active, not recruiting

A Window of Opportunity Trial of Intratumoral Injection of Copaxone® in Patients With Percutaneously Accessible Tumors

Basal Cell Carcinoma | Squamous Cell Carcinoma | Cutaneous Squamous Cell Carcinoma

United States
Sheba Medical Center

Unknown

An Open Label, Exploratory Study to Investigate the Treatment Effect of Glatiramer Acetate on Girls Woth Rett Syndrome

Rett Syndrome

Israel
AJU Pharm Co., Ltd.

Completed

The Drug-drug Interaction Study of AJU-A51R1 and AJU-A51R2

T2DM (Type 2 Diabetes Mellitus)

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute
Anixa Biosciences, Inc.

Recruiting

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer

Ovarian Cancer

United States
Baylor College of Medicine
Shriners Hospitals for Children

Withdrawn

Probiotics in Girls With Spina Bifida

Urinary Tract Infection

United States
Fondazione Poliambulanza Istituto Ospedaliero

Completed

Prevention of Hypoglycaemia by Oral 40% Destrogel

Hypoglycaemia Neonatal

Italy

Search clinical trials for: YYC506-T and YYC506-A (phase 1)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations